Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle
- PMID: 9630342
- PMCID: PMC1565354
- DOI: 10.1038/sj.bjp.0701792
Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle
Abstract
1. The effects of isoenzyme-selective inhibitors of phosphodiesterases PDE3 and PDE4 on cyclic AMP concentration, two indices of phosphoinositide hydrolysis, and contractile responses to spasmogens have been investigated in bovine tracheal smooth muscle (BTSM). 2. Neither the PDE3-selective inhibitor ORG 9935, nor the PDE4-selective inhibitor rolipram increased cyclic AMP levels in BTSM. However, rolipram addition in the presence of PDE3 inhibition (ORG 9935; 1 microM) concentration-dependently (-log EC50 (M), 6.55+/-0.15; n = 3) increased cyclic AMP levels to about 70% of the maximal response to the beta-adrenoceptor agonist isoprenaline. 3. Rolipram per se inhibited histamine-stimulated [3H]-inositol (poly)phosphate ([3H]-InsP(X)) accumulation by > 80% (-log EC50 (M), 6.92+/-0.11; n = 3). Although ORG 9935 (1 microM) had little effect on histamine-stimulated [3H]-InsP(X) accumulation alone it greatly facilitated the inhibitory action of rolipram (-log EC50 (M), 8.82+/-0.39; n = 3). The effects of PDE3 and/or PDE4 inhibition on [3H]-InsP(X) accumulation stimulated by muscarinic acetylcholine (mACh) receptor activation were less marked. However, combined PDE3/4 inhibition significantly decreased this response at a submaximal concentration of mACh receptor agonist (carbachol; 1 microM). 4. The greater-than-additive effect of combined PDE3/4 inhibition was also observed at the level of contractile responses to histamine and carbachol. In experiments designed to investigate the effects of PDE3 and/or 4 inhibitors on the carbachol-mediated phasic contraction, additions of rolipram (10 microM) or ORG 9935 (1 microM) were without effect, whereas added together the inhibitors caused a significant (P < 0.01) 40% reduction in the peak phasic contractile response. 5. The effect on contraction correlated with a substantial inhibitory effect of PDE3/4 inhibition on the initial increase in inositol 1,4,5-trisphosphate (InsP3) accumulation stimulated by spasmogen. Thus, in the presence of ORG 9935 (1 microM) rolipram concentration-dependently inhibited carbachol-stimulated InsP3 accumulation by > or = 50% (-log EC50 (M), 6.77+/-0.21; n = 4). 6. Carbachol (100 microM) addition caused a rapid decrease (by 67% at 10 s) in BTSM cyclic AMP level in the presence of PDE3/4 inhibition. However, omission of Ca2+ from the incubation medium prevented the carbachol-evoked decrease in cyclic AMP and this coincided with a greater inhibition (> or = 80%) of the carbachol-stimulated InsP3 response. 7. These data indicate that combined PDE3 and PDE4 inhibition has greater-than-additive effects on second messenger and functional responses to spasmogens in BTSM. Furthermore, the ability of PDE3/4 inhibition significantly to attenuate mACh receptor-mediated contractile responses, may be, at least in part, attributed to an effect exerted at the level of InsP3 generation.
Similar articles
-
Regulation of phosphoinositide turnover in neonatal rat cerebral cortex by group I- and II- selective metabotropic glutamate receptor agonists.Br J Pharmacol. 1998 Feb;123(3):581-9. doi: 10.1038/sj.bjp.0701626. Br J Pharmacol. 1998. PMID: 9504400 Free PMC article.
-
Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.Br J Pharmacol. 1998 May;124(1):229-37. doi: 10.1038/sj.bjp.0701833. Br J Pharmacol. 1998. PMID: 9630364 Free PMC article.
-
Muscarinic receptors in canine colonic circular smooth muscle. II. Signal transduction pathways.Mol Pharmacol. 1991 Dec;40(6):952-9. Mol Pharmacol. 1991. PMID: 1661840
-
Phosphodiesterase inhibitors in airways disease.Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. doi: 10.1016/j.ejphar.2005.12.059. Epub 2006 Feb 2. Eur J Pharmacol. 2006. PMID: 16458289 Review.
-
Phosphoinositide metabolism in airway smooth muscle.Am Rev Respir Dis. 1990 Mar;141(3 Pt 2):S137-40. doi: 10.1164/ajrccm/141.3_Pt_2.S137. Am Rev Respir Dis. 1990. PMID: 2155561 Review.
Cited by
-
Effect of Roflumilast on Airway Blood Flow in COPD: A Pilot Study.Chronic Obstr Pulm Dis. 2017 Aug 28;4(4):262-264. doi: 10.15326/jcopdf.4.4.2017.0151. Chronic Obstr Pulm Dis. 2017. PMID: 29354670 Free PMC article. No abstract available.
-
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. Am J Respir Crit Care Med. 2023. PMID: 37364283 Free PMC article. Clinical Trial.
-
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.Drugs. 2021 Nov;81(16):1821-1830. doi: 10.1007/s40265-021-01616-9. Epub 2021 Nov 3. Drugs. 2021. PMID: 34731461 Review.
-
Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.Br J Pharmacol. 2008 May;154(1):82-92. doi: 10.1038/bjp.2008.56. Epub 2008 Mar 3. Br J Pharmacol. 2008. PMID: 18311187 Free PMC article.
-
Phosphodiesterase Inhibition as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease: Where We Have Been and What Lies Ahead.Chronic Obstr Pulm Dis. 2025 Jan 29;12(1):82-92. doi: 10.15326/jcopdf.2024.0559. Chronic Obstr Pulm Dis. 2025. PMID: 39688360 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous